Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 9,039 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pulmonary Clear all
Recruiting Phase 1Phase 2 Interventional

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

NCT07012031
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sotorasib, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Sacramento, California • Tampa, Florida • Wesley Chapel, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 30, 2026, 9:23 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

NCT04210037
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
APG-1252, Paclitaxel
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Plantation, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 30, 2026, 9:23 PM EDT
Active, not recruiting No phase listed Observational

CareCOPD - COPD Home Monitoring Study

NCT04918095
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
CareCOPD Platform
Device
Lead sponsor
Cognita Labs LLC
Industry
Eligibility
40 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 9:23 PM EDT
Completed Not applicable Interventional

Minimizing Pathologic Aspiration in Patients Undergoing Esophageal and Lung Resections for Cancer

NCT04251312
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer
Interventions
Oral Hygiene Education and Oral Hygiene Packets
Other
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 30, 2026, 9:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens

NCT01648166
View directory record Official record
Conditions
Lung Cancer
Interventions
Environmental sampling
Other
Lead sponsor
Susanne Arnold
Other
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 30, 2026, 9:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

NCT05438329
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
DB-1305/BNT325, Pembrolizumab, BNT327
Drug · Combination Product
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
42
States / cities
Bullhead City, Arizona • Cerritos, California • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 30, 2026, 9:23 PM EDT
Active, not recruiting Phase 3 Interventional

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

NCT05633602
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Chemotherapy, Pembrolizumab, Ramucirumab
Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
566
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 442 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 30, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

NCT02525653
View directory record Official record
Conditions
Lung Cancer, Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
Interventions
albumin-bound paclitaxel, gemcitabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Miami, Florida • Basking Ridge, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 30, 2026, 9:23 PM EDT
Not listed No phase listed Observational

Tissue Collection Study for Patients With Non-Small Cell Lung Cancer With Resectable Disease

NCT01450553
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Precision Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
7
States / cities
Birmingham, Alabama • Stuart, Florida • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 30, 2026, 9:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

NCT04988295
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lazertinib, Amivantamab, Pemetrexed, Carboplatin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
28
States / cities
Mobile, Alabama • Tucson, Arizona • Duarte, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 9:23 PM EDT
Completed Phase 2 Interventional

Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy

NCT00379665
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cisplatin
Drug
Lead sponsor
Southwestern Regional Medical Center
Other
Eligibility
20 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 30, 2026, 9:23 PM EDT
Completed Phase 1 Interventional

Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00104767
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 30, 2026, 9:23 PM EDT
Completed Phase 1 Interventional Results available

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

NCT00441337
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer, Prostate Cancer
Interventions
MDX-1106
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • Detroit, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 30, 2026, 9:23 PM EDT
Terminated Phase 2 Interventional

Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer

NCT00003495
View directory record Official record
Conditions
Stage IV Lung Cancer
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 30, 2026, 9:23 PM EDT
Terminated Phase 1 Interventional

Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection

NCT04526912
View directory record Official record
Conditions
Acute Lung Injury
Interventions
VIB7734, Placebo
Drug
Lead sponsor
Viela Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 30, 2026, 9:23 PM EDT
Terminated No phase listed Observational

Multiplex Microarray Chip-Based Diagnosis of Respiratory Infections

NCT01212042
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 30, 2026, 9:23 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT04092283
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
829
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 549 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 9:23 PM EDT
Recruiting Not applicable Interventional

Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade

NCT07661966
View directory record Official record
Conditions
Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer)
Interventions
Bright Light Therapy
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 30, 2026, 9:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)

NCT01100931
View directory record Official record
Conditions
NSCLC, Solid Tumors
Interventions
YM155, Carboplatin, Paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 30, 2026, 9:23 PM EDT
Recruiting Not applicable Interventional

Implementation of a Sarcopenia Clinic to Diagnose and Treat Skeletal Muscle Loss Due to COPD

NCT07059637
View directory record Official record
Conditions
COPD, Emphysema, Sarcopenia
Interventions
Multidisciplinary clinic evaluation, COPD standard of care
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 30, 2026, 9:23 PM EDT
Terminated No phase listed Observational

A Study to Evaluate Biomarkers in Chronic Obstructive Pulmonary Disease

NCT01268072
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
MedImmune LLC
Industry
Eligibility
40 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Baltimore, Maryland • Springfield, Massachusetts • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 30, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

NCT01685801
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo-matched-to-ivacaftor tablet
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 30, 2026, 9:23 PM EDT
Terminated No phase listed Observational

Measuring the Effect of Radiation Therapy on Patient Activity Levels

NCT02694380
View directory record Official record
Conditions
Head and Neck Cancer, Prostate Cancer, Breast Cancer, Lung Cancer
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 30, 2026, 9:23 PM EDT
Recruiting Phase 2Phase 3 Interventional

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

NCT04613596
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions
Adagrasib, Pembrolizumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
220
States / cities
Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 9:23 PM EDT